Medical Chemical Formulation and Manufacturing

The contract involves the manufacture of a modified 0.125 percent sodium hypochlorite solution, known as Dakins Solution Quarter Strength, packaged in 480 mL bottles. The scope includes full formulation development, rigorous quality control protocols, batch-by-batch testing to ensure consistency and safety, and strict compliance with medical-grade standards to meet regulatory requirements for clinical use. All production activities must adhere to guidelines ensuring sterility, stability, and purity, as the final product is intended for medical applications requiring precise chemical concentrations and contamination-free packaging. The contract is classified as a subcontract under NAICS code 325412 for pharmaceutical and medicine manufacturing, issued by the Department of Defense through the Medical Supply Chain Pharm FSA. It was posted on July 20, 2026, with a response deadline of July 27, 2026, and the performance location is not specified, implying flexibility in manufacturing site selection as long as compliance and delivery standards are met. The solicitation is accessible through the DIBBS platform, and while no set-aside provisions or point of contact information is provided, bidders are expected to demonstrate proven capability in producing pharmaceutical-grade chemical solutions with validated quality systems and documented adherence to medical manufacturing regulations.